Management of acute nonvariceal upper gastrointestinal bleeding: current policies and future perspectives

Area of Science:

• Gastroenterology
• Internal Medicine

Background:

• Acute upper gastrointestinal bleeding (UGIB) is a critical medical emergency with significant mortality rates.
• Peptic ulcers, frequently linked to NSAID use and H. pylori infection, are the primary cause of UGIB.
• Endoscopy is the standard diagnostic and therapeutic tool for UGIB, recommended within 24 hours of patient presentation.

Purpose of the Study:

• To evaluate the impact of proton pump inhibitor (PPI) therapy on the management and outcomes of acute upper gastrointestinal bleeding.
• To assess the efficacy of endoscopic therapy and post-endoscopic PPI administration in reducing rebleeding and mortality.

Main Methods:

• Review of current guidelines and clinical evidence regarding UGIB management.
• Analysis of the role of pre-endoscopic PPI administration in downstaging bleeding lesions.
• Evaluation of endoscopic treatment modalities for high-risk ulcers and the effect of high-dose post-endoscopic PPI therapy.

Main Results:

• Pre-endoscopic PPI administration can reduce the need for endoscopic therapy but does not impact rebleeding, mortality, or surgical rates.
• Endoscopic therapy is crucial for ulcers exhibiting high-risk stigmata to mitigate rebleeding risk.
• High-dose PPI therapy post-endoscopy is effective in preventing rebleeding and reducing mortality, especially in high-risk patients.

Conclusions:

• While pre-endoscopic PPIs have a limited role, endoscopic intervention for high-risk ulcers is vital.
• High-dose post-endoscopic PPI therapy significantly improves outcomes by preventing rebleeding and reducing mortality in patients with high-risk UGIB stigmata.